Please assess the completion status of the following clinical trial:

Trial Title: TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed hepatocellular carcinoma~* At least 1 previously unirradiated, bidimensionally measurable lesion greater than 20 mm by MRI or conventional CT scan OR at least 10 mm by spiral CT scan~* Patients with CNS involvement must have completed appropriate treatment and have no progressive neurologic deficits within the past 28 days~* No carcinomatous meningitis~PATIENT CHARACTERISTICS:~Age~* 18 to 80~Performance status~* ECOG 0-2~Life expectancy~* More than 12 weeks~Hematopoietic~* Hemoglobin ≥ 10.0 g/dL~* WBC ≥ 2,000/mm\^3~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 40,000/mm\^3~* No abnormal bleeding or clotting~Hepatic~* No grade C Child-Pugh cirrhosis~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Albumin ≥ 2.8 g/dL~* INR ≤ 1.5 times ULN~* Bilirubin ≤ 2.0 mg/dL~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No prior deep vein thrombosis~* No prior superficial venous thrombosis~* No family history of thromboembolism in a first-degree relative~* No lower extremity thromboses by Doppler ultrasound (unless a subsequent venous angiography confirms a false positive ultrasound)~Pulmonary~* No prior pulmonary embolism~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception, except oral contraceptives containing estrogen~* Fasting triglycerides ≤ 400 mg/dL for men or ≤ 325 mg/dL for women~* No other malignancy within the past 3 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix~* No uncontrolled metabolic disorders, other nonmalignant organ or systemic disease, or secondary effects of cancer that induce a high medical risk~* No known allergy or hypersensitivity to TAC-101 or its components~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior thalidomide~* No prior putative antiangiogenesis therapy~* Prior interferon allowed~Chemotherapy~* No more than 2 prior chemotherapy regimens~Endocrine therapy~* No concurrent estrogen products~Radiotherapy~* See Disease Characteristics~* More than 21 days since prior radiotherapy, except small portal radiotherapy used for the palliation of isolated, symptomatic, osseous metastases~* No prior radiotherapy to evaluable lesions~* No concurrent radiotherapy unless for bone pain that is present before beginning study~Surgery~* Not specified~Other~* Prior anticancer treatment allowed provided there is clear evidence of progressive disease after the most recent treatment~* More than 21 days since prior anticancer therapy and recovered~* No more than 2 prior treatment regimens~* No concurrent therapeutic anticoagulants~  * Concurrent low-dose warfarin for prophylactic care of indwelling venous access devices allowed~* No concurrent azoles or tetracyclines~* No concurrent medications known or suspected to increase risk of venous thromboembolism~* No other concurrent retinoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TAC-101 (Type: EXPERIMENTAL): Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete